• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

    1/22/25 8:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TENX alert in real time by email

    CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations.

    Ms. Andor will lead the Company's expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).

    "We are pleased to welcome Gillian to the Tenax team at a critical time for our Company, as we continue to enroll patients in the Phase 3 LEVEL study and finalize plans to initiate our second pivotal study," said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. "We believe Gillian's significant experience executing clinical development programs resulting in NDA submissions and approvals will help us accelerate our Phase 3 program, and ensure we are prepared for global regulatory filings."

    Ms. Andor has over 20 years of experience in Clinical Operations. She served most recently as Interim Head, Clinical Development Operations with Noema Pharma, focused on CNS disorders, where she led Clinical Operations and Data Management functions. Prior, she served as Head of Portfolio Operations for Sage Therapeutics, achieving multiple promotions during her nine-year tenure and building a high-functioning Clinical Operations department. Ms. Andor led and supervised the global clinical development programs across Sage's portfolio in neurology and CNS disorders including successful NDA submissions and approvals for Zulresso® and Zurzuvae®, the first approved medications for postpartum depression. Prior to joining Sage, Ms. Andor held multiple positions within Clinical Operations for Ironwood Pharmaceuticals where she successfully planned, managed, and executed U.S. and European clinical studies in GI disorders, most notably contributing to the NDA and approval of Linzess® for IBS-C.

    Ms. Andor received a BSc Anatomy (Honors) from the University of Glasgow, where she finished with first class honors, and an MSc in Forensic Science from the University of Strathclyde.

    Tenax Therapeutics also announced the issuance on January 21, 2025 of an inducement equity award to Ms. Andor in connection with her appointment to the position of Vice President, Clinical Operations of the Company effective the same day. The award consists of an option to purchase 250,000 shares of the Company's common stock. The award will vest in four equal annual installments beginning on the first anniversary of the date of issuance, subject to Ms. Andor's continued employment with the Company through each applicable vesting date. The exercise price for the option is $6.44. The award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).

    About Tenax Therapeutics

    Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns global rights to develop and commercialize levosimendan, which it has prioritized in the near term. Tenax Therapeutics also may resume developing its unique oral formulation of imatinib. For more information, visit www.tenaxthera.com. Tenax Therapeutics' common stock is listed on The Nasdaq Stock Market LLC under the symbol "TENX".

    Caution Regarding Forward-Looking Statements

    Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements may include information concerning possible or projected future business operations. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: our ability to maintain our culture and recruit, integrate and retain qualified personnel and advisors, including on our Board of Directors; risks related to our business strategy, including the prioritization and development of product candidates; risks of our clinical trials, including, but not limited to, the timing, delays, costs, design, initiation, enrollment, and results of such trials; any delays in regulatory review and approval of product candidates in development; reliance on third parties, including Orion Corporation, our manufacturers and CROs; risks regarding the formulation, production, marketing, customer acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; the potential advantages of our product candidates; risks associated with our cash needs; our competitive position; intellectual property risks; volatility and uncertainty in the global economy and financial markets in light of the possibility of pandemics, global financial and geopolitical uncertainties, including in the Middle East and the Russian invasion of and war against the country of Ukraine; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and other risks and uncertainties set forth from time to time in our SEC filings. Tenax Therapeutics assumes no obligation and does not intend to update these forward-looking statements except as required by law.

    Contacts

    Investor Contact:

    John Fraunces

    Managing Director

    LifeSci Advisors, LLC

    C: 917-355-2395

    [email protected]

    or

    Brian Mullen

    LifeSci Advisors, LLC

    C: 203-461-1175

    [email protected]



    Primary Logo

    Get the next $TENX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TENX

    DatePrice TargetRatingAnalyst
    10/24/2024$16.00Outperform
    Leerink Partners
    10/14/2024$16.00Buy
    Guggenheim
    9/30/2024Outperform
    William Blair
    More analyst ratings

    $TENX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tenax Therapeutics Inc.

      SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

      11/14/24 7:14:21 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

      SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

      11/14/24 12:21:05 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

      SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

      11/13/24 5:35:29 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Tenax Therapeutics Inc.

      DEFA14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

      4/25/25 7:45:16 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Tenax Therapeutics Inc.

      DEF 14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

      4/25/25 7:42:43 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Tenax Therapeutics Inc.

      EFFECT - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

      4/24/25 12:15:09 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Tenax Therapeutics with a new price target

      Leerink Partners initiated coverage of Tenax Therapeutics with a rating of Outperform and set a new price target of $16.00

      10/24/24 6:39:21 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Tenax Therapeutics with a new price target

      Guggenheim initiated coverage of Tenax Therapeutics with a rating of Buy and set a new price target of $16.00

      10/14/24 7:43:13 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Tenax Therapeutics

      William Blair initiated coverage of Tenax Therapeutics with a rating of Outperform

      9/30/24 7:51:49 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

      CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025. Details of presentation: Format: Corporate Presentation Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer, Doug Randall, Chief Business Officer Date and Time: April 7, 2025, at 3:45 p.m. ET The live and archived webcast of

      3/31/25 8:00:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027 Phase 3 LEVEL Study Expansion Increases Statistical Power; Enrollment Completion Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies,

      3/25/25 4:05:00 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Announces $25 Million Private Placement

      CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) (the "Company" or "Tenax Therapeutics"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting placement agent fees and other private placement expenses. The private placement will be for an aggregate of 378,346 shares of the Company's common stock and pre-funded warrants to purchase an aggrega

      3/5/25 8:47:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Leadership Updates

    Live Leadership Updates

    See more

    $TENX
    Financials

    Live finance-specific insights

    See more

    $TENX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

      CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations. Ms. Andor will lead the Company's expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). "We are

      1/22/25 8:00:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

      -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

      11/4/24 7:30:00 AM ET
      $ATNM
      $AVTX
      $RDHL
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board

      CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company's PH-HFpEF Scientific Advisory Board (SAB). "We are thrilled to welcome Dr. Butler to our Scientific Advisory Board," said Stuart Rich, M.D., Chief Medical Officer of Tenax Therapeutics. "Javed is regarded as one of the most eminent clinical trialists in cardiovascular medicine, and he joins three highly distinguished cardiovascular lead

      11/17/23 8:30:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

      Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update. "Having completed the merger with PHPrecisionMed Inc., we now have product development programs in group one and group two pulmonary hypertension patients," stated Anthony DiTonno, Chief Executive Officer of Tenax, "which represent more than 70% of the overall market. "We have begun the open label transition study using the oral formulation of Levosimendan, which was recently acq

      5/17/21 5:15:00 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med

      MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH). The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need. The acquisition expands Tenax’s pulmonary hypertension pipeline with the addition of imatinib, a Phase 3 ready candidate. Imatinib is a tyrosine kinase i

      1/19/21 7:45:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Proehl Gerald T bought 1,666 shares, increasing direct ownership by 166,600% to 1,667 units (SEC Form 4)

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      8/8/24 7:43:25 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Davidson Michael H. bought 2,500 shares, increasing direct ownership by 656% to 2,881 units (SEC Form 4)

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      8/8/24 7:42:23 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by no longer 10% owner Dellora Investments Lp

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      3/12/25 5:26:30 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Dellora Investments Lp claimed ownership of 351,071 shares (SEC Form 3)

      3 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      1/10/25 4:27:18 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Rich Stuart

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      12/12/24 8:09:56 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care